Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

Dow Jones

2025/10/01

0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

October 01, 2025 02:47 ET (06:47 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572586539"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572586539\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572586539?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 14:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572586539","market":"hk","top_or_hot":-1,"title":"Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-01 14:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 01, 2025 02:47 ET (06:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572586539","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572586539","pubTimestamp":1759301220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4578":"CAR-T","NVS":"诺华","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4532":"文艺复兴科技持仓","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC"},"translate_title":"诺华首次获得FDA批准Rhapsido，后续可能会有更多批准——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0646 GMT - Novartis's Rhapsido received approval from the U.S. Food and Drug Administration to treat hives, but the drug is also being evaluated in other conditions that could expand the company's immunology and neuroscience portfolios, Vontobel's Stefan Schneider says. Sales for Rhapsido--commercial name of the drug known until now as remibrutinib--in spontaneous hives, or urticaria, could hit $1.75 billion, according to Vontobel. The Swiss pharmaceutical company is also conducting trials for food allergy and other skin conditions that could expand its immunology portfolio, the analyst says in a research note. The drug is also being studied for multiple sclerosis and myasthenia, which could support growth in Novartis's neuroscience portfolio, he says. Line extensions are likely to make up a large chunk of Novartis's upcoming updates, Vontobel says. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 01, 2025 02:47 ET (06:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}